Advertisement

Hypofractionated whole-breast radiotherapy and concomitant boost after breast conservation in elderly patients

Abstract

Aims

To report the 5- and 10-year results of accelerated hypofractionated whole-breast radiotherapy (WBRT) with concomitant boost to the tumor bed in 83 consecutive patients with early breast cancer aged >70 years.

Methods

All patients were treated with breast conservation and hypofractionated WBRT. The prescription dose to the whole breast was 45 Gy (2.25 Gy/20 fractions) with an additional daily concomitant boost of 0.25 Gy to the surgical cavity (2.5 Gy/20 fractions up to 50 Gy). The maximum detected toxicity was scored according to the Common Terminology Criteria for Adverse Events, version 3.0. We considered as skin toxicity: erythema, edema, desquamation, ulceration, hemorrhage, necrosis, telangiectasia, fibrosis-induration, hyperpigmentation, retraction and atrophy. Cosmetic results were assessed as set by the Harvard criteria.

Results

With a median follow-up of 60 months (range 36-88), no local recurrence was observed. The maximum detected acute skin toxicity was G0 in 57% of patients, G1 in 40% and G2 in 3%. Late skin and subcutaneous toxicity was generally mild with no ≥G3 events. The cosmetic results were excellent in 69% of patients, good in 22%, fair in 5%, and poor in 4%.

Conclusions

The present results support the use of hypofractionation employing a concomitant boost to the lumpectomy cavity in women aged >70 years. This is a convenient treatment option for both this type of population and health-care providers.

Tumori 2016; 102(2): 196 - 202

Article Type: ORIGINAL RESEARCH ARTICLE

DOI:10.5301/tj.5000402

Authors

Domenico Cante, Pierfrancesco Franco, Piera Sciacero, Giuseppe Girelli, Massimo Pasquino, Valeria Casanova Borca, Santi Tofani, Maria Rosa La Porta, Umberto Ricardi

Article History

Disclosures

Financial support: None to declare.
Conflict of interest: The authors declare they do not have any conflict of interest.

This article is available as full text PDF.

  • If you are a Subscriber, please log in now.

  • Article price: Eur 36,00
  • You will be granted access to the article for 72 hours and you will be able to download any format (PDF or ePUB). The article will be available in your login area under "My PayPerView". You will need to register a new account (unless you already own an account with this journal), and you will be guided through our online shop. Online purchases are paid by Credit Card through PayPal.
  • If you are not a Subscriber you may:
  • Subscribe to this journal
  • Unlimited access to all our archives, 24 hour a day, every day of the week.

Authors

Affiliations

  • Radiotherapy Department, Ivrea Community Hospital, ASL TO4, Ivrea - Italy
  • Department of Oncology – Radiation Oncology, University of Turin, Turin - Italy
  • Medical Physics Department, Ivrea Community Hospital, ASL TO4, Ivrea - Italy

Article usage statistics

The blue line displays unique views in the time frame indicated.
The yellow line displays unique downloads.
Views and downloads are counted only once per session.

No supplementary material is available for this article.